Last reviewed · How we verify

Hypocalcemic tetany — Treatment Landscape & Competitive Intelligence

Hypocalcemic tetany (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hypocalcemic tetany, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Phoslo CALCIUM ACETATE Fresenius Medcl Care calcium acetate 1982-01-01
Calcium Gluceptate calcium glucoheptonate Abbott calcium glucoheptonate 1972-01-01
Plegisol In Plastic Container CALCIUM CHLORIDE Pfizer calcium chloride 1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Hypocalcemic tetany
  2. Abbott · 1 drug in Hypocalcemic tetany
  3. Fresenius Medcl Care · 1 drug in Hypocalcemic tetany
  4. Pfizer · 1 drug in Hypocalcemic tetany

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hypocalcemic tetany:

Cite this brief

Drug Landscape (2026). Hypocalcemic tetany — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hypocalcemic-tetany. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing